Kurzfassung

A Phase 3 , multicenter, randomized, double-blind, parallel-group, , placebo-and active-controlled study followed by a placebo-controlled maintenance period and open-label follow-up to evaluate the efficavy and safety of certolizumab pegol in subjects with moderate to severe chronic plaque psoriasis